We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioNTech SE Sponsored ADR (BNTX) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, BioNTech SE Sponsored ADR (BNTX - Free Report) closed at $170.26, marking a +0.68% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.27%. Meanwhile, the Dow gained 0.4%, and the Nasdaq, a tech-heavy index, lost 0.18%.
Coming into today, shares of the company had gained 23.19% in the past month. In that same time, the Medical sector gained 9.59%, while the S&P 500 gained 7.36%.
Investors will be hoping for strength from BioNTech SE Sponsored ADR as it approaches its next earnings release. The company is expected to report EPS of $9.84, up 86.01% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $4.68 billion, up 89.34% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $32.69 per share and revenue of $16.48 billion, which would represent changes of -30.28% and -26.32%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for BioNTech SE Sponsored ADR. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.35% lower. BioNTech SE Sponsored ADR is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that BioNTech SE Sponsored ADR has a Forward P/E ratio of 5.17 right now. Its industry sports an average Forward P/E of 22.94, so we one might conclude that BioNTech SE Sponsored ADR is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 151, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
BioNTech SE Sponsored ADR (BNTX) Gains As Market Dips: What You Should Know
In the latest trading session, BioNTech SE Sponsored ADR (BNTX - Free Report) closed at $170.26, marking a +0.68% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.27%. Meanwhile, the Dow gained 0.4%, and the Nasdaq, a tech-heavy index, lost 0.18%.
Coming into today, shares of the company had gained 23.19% in the past month. In that same time, the Medical sector gained 9.59%, while the S&P 500 gained 7.36%.
Investors will be hoping for strength from BioNTech SE Sponsored ADR as it approaches its next earnings release. The company is expected to report EPS of $9.84, up 86.01% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $4.68 billion, up 89.34% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $32.69 per share and revenue of $16.48 billion, which would represent changes of -30.28% and -26.32%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for BioNTech SE Sponsored ADR. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.35% lower. BioNTech SE Sponsored ADR is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that BioNTech SE Sponsored ADR has a Forward P/E ratio of 5.17 right now. Its industry sports an average Forward P/E of 22.94, so we one might conclude that BioNTech SE Sponsored ADR is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 151, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.